Drugs for Biological Treatment 2026 Tender

• Country: Slovakia
• Summary: Drugs for Biological Treatment 2026
• SKT Ref No: 139859854
• Deadline: 25 May 2026
• Financier: Self Financed
• Purchaser Ownership: Government
• Tender Value: Refer Document
• Notice Type: Tender
• Document Ref. No.: 269912-2026
• Purchaser's Detail:
  Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.

  Login to see details
• Description:
• Part 1: Belimumab Part 2: Abatacept Part 3: Infliximab Part 4: Tocilizumab Part 5: Anifrolumab Part 6: Rituximab The subject of the contract is the supply of drugs for biological treatment. A detailed definition of the subject of the contract is given in section B.1 "Description of the subject of the contract" a B.2 "Commercial conditions of delivery of the subject of the contract", tender documents. The subject of the given part of the subject of the contract is the supply of the drug with the active ingredient Belimumab in accordance with the specification given in part B.1 "Description of the subject of the contract" and B.2 "Commercial conditions of delivery of the subject of the contract", tender documents. The subject of the given part of the subject of the contract is the supply of a medicine with the active substance Abatacept in the sense of the specification given in part B.1 "Description of the subject of the contract" and B.2 "Business conditions of delivery of the subject of the contract", tender documents. The subject of the given part of the subject of the contract is the supply of the drug with the active substance Infliximab in accordance with the specification given in part B.1 "Description of the subject of the contract" and B.2 "Business conditions of delivery of the subject of the contract", tender documents. Subject of the given part the subject of the contract is the supply of a medicine with the active ingredient Tocilizumab in accordance with the specification given in part B.1 "Description of the subject of the contract" and B.2 "Business conditions of delivery of the subject of the contract", tender documents. The subject of the given part of the subject of the contract is the delivery of the medicine with the active substance Anifrolumab in the sense of the specification given in part B.1 "Description of the subject of the contract" and B.2 "Commercial terms of delivery of the subject of the contract", tender documents. The subject of the...
• Documents:

 Tender Notice